September 2018 FDA Recall Lamotrigine by Torrent Pharma Inc.
D-1204-2018 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Torrent Pharma Inc. on September 11, 2018 for the product Lamotrigine. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1204-2018

Reason for Recall
Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.
Initiated
09-11-2018
Reported
09-26-2018
Quantity
15,384 30-count bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured in INDIA, For: TORRENT PHARMA INC., 150 Allen Road, Suite 102, Basking Ridge, NJ 07920. NDC: 13668-342-30

Batch or Lot Expiration Information

Lot# Lot: BFR5D002 EXP 11-2019